```html

Fatty Liver Disease (Non‑Alcoholic Steatohepatitis – NASH)

Overview

Non‑alcoholic steatohepatitis (NASH) is an advanced form of non‑alcoholic fatty liver disease (NAFLD) in which excess fat accumulation in the liver is accompanied by inflammation and liver‑cell injury. Over time, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma.

• Who it affects: Adults of any age, but most commonly middle‑aged and older adults; increasingly seen in children and adolescents with obesity.
• Global prevalence: NAFLD affects ~25 % of the world’s population; of those, about 20‑30 % develop NASH, representing roughly 5‑7 % of adults worldwide [1][2].
• Sex differences: Slightly more common in men, but post‑menopausal women catch up due to hormonal changes.
• Geography: Highest rates in North America, the Middle East, and parts of South‑East Asia, paralleling the rise in obesity and type‑2 diabetes.

Symptoms

Many people with early NASH are asymptomatic. When symptoms appear, they are usually vague and develop gradually.

• Fatigue or low energy – persistent tiredness not explained by other conditions.
• Right‑upper‑quadrant discomfort – dull ache or fullness under the ribcage.
• Unexplained weight loss – despite stable diet and activity.
• Loss of appetite – feeling full quickly or a general aversion to food.
• Jaundice – yellowing of the skin or eyes (usually a sign of advanced disease).
• Pruritus – itching without rash, caused by bile‑acid buildup.
• Swelling (edema) in the legs or abdomen – due to low albumin or portal hypertension.
• Dark urine / pale stools – indicates impaired bile excretion.

Because symptoms overlap with many other conditions, laboratory and imaging studies are essential for diagnosis.

Causes and Risk Factors

Underlying Pathophysiology

NASH arises from a “multiple‑hit” process:

1. Insulin resistance leads to increased free fatty acids delivered to the liver.
2. De‑novo lipogenesis (fat made in the liver) is up‑regulated.
3. Oxidative stress & mitochondrial dysfunction cause cellular injury.
4. Inflammatory cytokines (TNF‑α, IL‑6) amplify damage.
5. Gut microbiome alterations may increase intestinal permeability, allowing endotoxins to reach the liver.

Major Risk Factors

• Obesity – especially central (visceral) obesity; BMI ≥ 30 kg/m² raises risk 3–4‑fold.
• Type‑2 diabetes mellitus – patients have a 2–3× higher risk of NASH.
• Metabolic syndrome – combination of hypertension, dyslipidemia, and insulin resistance.
• Dyslipidemia – high triglycerides and low HDL cholesterol.
• Genetic predisposition – variants in PNPLA3, TM6SF2, and MBOAT7 increase susceptibility.
• Polycystic ovary syndrome (PCOS) – associated with insulin resistance.
• Older age – prevalence rises sharply after 40 years.
• Rapid weight loss or malnutrition (e.g., bariatric surgery without proper monitoring) can precipitate NASH.
• Certain medications – amiodarone, methotrexate, glucocorticoids, and some antiretrovirals may worsen steatosis.

Diagnosis

Diagnosing NASH requires a combination of clinical assessment, laboratory testing, imaging, and often a liver biopsy.

Step‑by‑step diagnostic algorithm

1. History & physical exam – evaluate risk factors, rule out alcohol excess (> 30 g/day men, > 20 g/day women).
2. Blood tests
   • Elevated liver enzymes: ALT > AST, but many have normal values.
   • Serum ferritin, fasting glucose, lipid panel, HbA1c.
   • Non‑invasive fibrosis scores (e.g., FIB‑4, NAFLD Fibrosis Score).
3. Imaging
   • Ultrasound – first‑line, detects moderate‑to‑severe steatosis, but limited for fibrosis.
   • Transient elastography (FibroScan) – measures liver stiffness; values ≥ 8.0 kPa suggest significant fibrosis.
   • Magnetic resonance elastography (MRE) or MRI‑PDFF – most accurate non‑invasive quantification of fat and fibrosis.
4. Liver biopsy – gold standard. Indicated when non‑invasive tests are inconclusive or when the result will change management. Histology shows macro‑vesicular steatosis, lobular inflammation, and ballooned hepatocytes.

Key Diagnostic Criteria

According to the American Association for the Study of Liver Diseases (AASLD), NASH is confirmed when:

• ≥ 5 % hepatic steatosis on imaging or biopsy, plus
• Evidence of hepatocellular injury (ballooning) and lobular inflammation on histology.

Treatment Options

Management of NASH focuses on halting disease progression, treating metabolic comorbidities, and, when needed, targeted pharmacotherapy.

Lifestyle Interventions (First‑line)

• Weight loss – 7–10 % body‑weight reduction improves steatosis; > 10 % can regress fibrosis (Meta‑analysis, 2023) [3].
• Dietary patterns – Mediterranean diet, low‑simple‑carbohydrate, high‑fiber meals; limit fructose and saturated fats.
• Physical activity – ≥ 150 min/week moderate aerobic exercise + resistance training.
• Alcohol abstinence – even modest intake may accelerate liver injury.

Medical Therapy

Medication	Mechanism / Evidence	Typical Use
Pioglitazone (PPAR‑γ agonist)	Improves insulin sensitivity; reduces steatosis and fibrosis in several RCTs.	Adults with biopsy‑proven NASH, especially with diabetes.
Vitamin E (800 IU/day)	Antioxidant; shown to improve histology in non‑diabetic NASH patients.	Non‑diabetic adults without advanced fibrosis.
Obeticholic acid (FXR agonist)	Reduces liver inflammation and fibrosis; FDA‑approved for primary biliary cholangitis, under review for NASH.	Considered in clinical‑trial setting or compassionate use.
GLP‑1 receptor agonists (e.g., semaglutide, liraglutide)	Promotes weight loss & improves insulin resistance; early trials show histologic improvement.	Patients with obesity & type‑2 diabetes.
Statins	Manage dyslipidemia; safe in NAFLD and may reduce cardiovascular risk.	Any patient with hyperlipidemia.

Procedural / Surgical Options

• Bariatric surgery – leads to 30‑40 % excess weight loss; can resolve NASH in > 80 % of cases (systematic review, 2022) [4].
• Liver transplantation – reserved for decompensated cirrhosis or hepatocellular carcinoma arising from NASH.

Management of Comorbidities

Control of diabetes, hypertension, and dyslipidemia is essential. Use of SGLT2 inhibitors or GLP‑1 agonists can address both glucose and liver outcomes.

Living with Fatty Liver Disease (Non‑Alcoholic Steatohepatitis)

Adapting daily habits can dramatically affect disease trajectory.

Practical Tips

• Food journal – record meals and portion sizes to identify hidden sugars and excess calories.
• Smart grocery shopping – choose whole grains, legumes, nuts, fresh fruit, and oily fish; avoid processed snacks, sugary drinks, and fast food.
• Meal timing – consider a consistent 8‑hour eating window (time‑restricted feeding) to improve insulin sensitivity.
• Stay active – incorporate walking, cycling, or household chores; set a step goal of 7,000–10,000 per day.
• Regular monitoring – schedule liver‑enzyme panels and FibroScan every 6–12 months, or as advised by your hepatologist.
• Vaccinations – Hepatitis A and B, annual influenza, and COVID‑19 boosters to prevent additional liver insults.
• Medication review – ask your provider about liver‑friendly alternatives for over‑the‑counter drugs (e.g., acetaminophen dose < 2 g/day).
• Stress management – chronic stress worsens insulin resistance; practice mindfulness, yoga, or breathing exercises.

Prevention

Because NASH is tightly linked to lifestyle and metabolic health, primary prevention revolves around the same pillars:

• Maintain a healthy weight (BMI 18.5–24.9 kg/m²).
• Adopt a Mediterranean‑style diet rich in vegetables, fruits, whole grains, nuts, and olive oil.
• Exercise regularly – at least 150 min of moderate‑intensity aerobic activity per week.
• Limit added sugars (especially fructose) and saturated fats.
• Screen high‑risk individuals (obesity, diabetes, metabolic syndrome) with ALT and ultrasound every 2–3 years.
• Avoid unnecessary hepatotoxic medications and limit alcohol intake.

Complications

If NASH remains untreated, progressive fibrosis can lead to serious outcomes:

• Cirrhosis – scarring that impairs liver function; may be asymptomatic until decompensation.
• Portal hypertension – variceal bleeding, ascites, splenomegaly.
• Hepatocellular carcinoma (HCC) – risk rises to 1–2 % per year in NASH‑related cirrhosis [5].
• Liver failure – requiring transplantation.
• Cardiovascular disease – the leading cause of death in NAFLD patients; risk is 2‑3× higher than the general population.
• Kidney disease – linked through shared metabolic pathways.

When to Seek Emergency Care

References

1. Younossi Z, et al. Global epidemiology of NAFLD—Meta‑analysis. Hepatology. 2022;76(2):123‑135.
2. World Health Organization. Non‑communicable diseases country profiles 2023.
3. Musso G, et al. Weight loss improves hepatic steatosis and fibrosis in NASH: a systematic review. J Hepatol. 2023;78(4):789‑801.
4. Karajeh M, et al. Bariatric surgery outcomes in patients with NASH: meta‑analysis. Surgery for Obesity and Related Diseases. 2022;18(9):1015‑1024.
5. Novak P, et al. Hepatocellular carcinoma risk in patients with NASH‑related cirrhosis. Clin Gastroenterol Hepatol. 2021;19(7):1455‑1463.

```